Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | BRAF | P15056 | 4/20 | 0.50 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | IDH2 | P48735 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273474 | 0.89 | TRPV1 (0.57) | KDRBRAFCDK8CA1CA2 | |
| SCHEMBL2434151 | 0.83 | PPIA (0.61) | KDRIDH2PPIA | |
| SCHEMBL3790500 | 0.78 | KDR (0.64) | KDRBRAFCDK8CA1CA2 | |
| SCHEMBL2437389 | 0.74 | GRM4 (0.41) | CDK8ARCTSVCTSLGRM4 | |
| SCHEMBL282336 | 0.73 | AR (0.62) | KDRBRAFCDK8ARGRM4 | |
| SCHEMBL27587718 | 0.73 | CXCR1 (0.71) | CA12CA1CA2CA9AR | |
| SCHEMBL4255007 | 0.73 | PPIA (0.64) | PPIA | |
| SCHEMBL21617292 | 0.73 | SIRT2 (0.55) | CTSVCTSL | |
| SCHEMBL31504452 | 0.73 | SIRT2 (0.55) | CTSVCTSL | |
| SCHEMBL4256172 | 0.72 | MEN1 (0.67) | CA12CA1CA2CA9CTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| EP-1945217-B1 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | disclosed |
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| CN-101693709-A | Bicyclic amides as kinase inhibitors | NOVARTIS AG | 2010-04-14 | — | — | CN | disclosed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | disclosed |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-11-20 | — | — | US | disclosed |
| EP-1945217-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | Novartis AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| CN-101018784-A | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2007-08-15 | — | — | CN | disclosed |
| EP-1794149-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885BRAF 178/4885CDK8 328/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | KDR 826/4885BRAF 26/4885CDK8 78/4885 |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | MAP3K20, MAP3K1, MAP3K19 | KDR 888/4885BRAF 25/4885CDK8 76/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885BRAF 178/4885CDK8 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.